source
- BioMarin to acquire Alesta Therapeutics for $275 million to expand bone disease pipelineBioMarin Pharmaceutical announced it will purchase Alesta Therapeutics for an upfront payment of $275 million. Alesta is developing an oral small-molecule drug, ALE1, aimed at treating hypophospha…
- Craif raises $33M to expand its urine-based pancreatic cancer testAI biopharma Craif announced a $33 million Series D financing, bringing its total capital raised to $88 million. The funding will be used to scale research on its urine-based microRNA test, miSign…